Lions Bay Mining Corp.
LMNGF
Other OTC0.24
USD
-0.02
- -
Lions Bay Mining Corp.
LMNGF
(Other OTC)
Recent
price
0.24
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Lions Bay Mining Corp. (OTCPK:LMNGF), formerly a mineral exploration company focused on precious metals projects such as the Fish Lake Valley property in North America, underwent a reverse takeover transaction in 2020 through which it acquired BioVaxys Inc. and rebranded as BioVaxys Technology Corp., shifting its primary business to the development of haptenized protein vaccines and immuno-diagnostics for antiviral and anticancer applications; its core products and services include the SARS-CoV-2 vaccine candidate BVX-0320, a haptenized S1 subunit spike protein vaccine eliciting antibody and T-cell responses, the ovarian cancer vaccine BVX-0918A utilizing bihaptenized autologous tumor cells for Stage III/IV patients, the CoviDTH diagnostic platform for detecting T-cell immunity to SARS-CoV-2 via delayed-type hypersensitivity testing, and associated intellectual property encompassing issued U.S. patents on haptenized tumor cell immunotherapy and cryopreservation along with pending applications for coronavirus spike proteins and cell-mediated immune response detection. The company, founded on April 25, 2018, and headquartered in Vancouver, British Columbia, Canada, with operations centered in North America and extending to clinical development partnerships in Europe, targets markets in infectious diseases, oncology, and immune diagnostics served through contract manufacturing organizations like WuXi Biologics and BioElpida, and regulatory engagements with the FDA and EU authorities. Recent major changes within the last two years encompass strategic collaborations including a 2021 heads of agreement with Procare Health Iberia for co-development and EU commercialization of ovarian, cervical, and HPV vaccines, bioproduction agreements with WuXi Biologics for SARS-CoV-2 proteins and BioElpida for GMP clinical-grade manufacturing of BVX-0918A, preclinical toxicology studies with Inotiv, patent expansions to cover SARS-CoV-2 variants and bihaptenized platforms across major jurisdictions, uplisting to OTCQB under BVAXF, private placements raising over C$2 million for vaccine advancement, and regulatory milestones such as FDA pre-IND meetings and compassionate use planning for ovarian cancer vaccines in the EU.